Anemia management in chronic kidney disease

Kidney International

Volumn 78, Issue SUPPL. 117, 2010, Pages

  Fishbane, Steven ^a,b   Nissenson, Allen R ^c,d  

^a WINTHROP UNIVERSITY HOSPITAL   (United States)

^b STONY BROOK UNIVERSITY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d DAVITA INC   (United States)

Author keywords

Anemia; ESA; health policy

Indexed keywords

ANTIEMETIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANDESARTAN; CARNITINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FOLIC ACID; HEMOGLOBIN; METOPROLOL; RAMIPRIL; RECOMBINANT ERYTHROPOIETIN; TRANSFERRIN; VITAMIN B GROUP; ANTIANEMIC AGENT;

ANEMIA; CHRONIC KIDNEY DISEASE; HEMODIALYSIS PATIENT; HUMAN; PATIENT CARE; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE; BIOSYNTHESIS; CHRONIC KIDNEY FAILURE; ECONOMICS; FOOD AND DRUG ADMINISTRATION; QUALITY OF LIFE; UNITED STATES;

ANEMIA; ERYTHROPOIETIN, RECOMBINANT; HEMATINICS; HEMOGLOBINS; HUMANS; KIDNEY FAILURE, CHRONIC; QUALITY OF LIFE; TREATMENT OUTCOME; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 77955139574     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2010.188     Document Type: Review

References (48)

1. Kazmi WH, Kausz AT, Khan S et al. Anemia: an early complication of chronic renal insufficiency. Am J Kidney Dis 2001; 38: 803-812.
2. Eschbach JW, Adamson JW. Anemia of end-stage renal disease (ESRD). Kidney Int 1985; 28: 1-5.
3. Lundin AP, Delano BG, Quinn-Cefaro R. Perspectives on the improvement of quality of life with epoetin alfa therapy. Pharmacotherapy 1990; 10 (2 Part 2): 22S-26S.
4. Regidor DL, Kopple JD, Kovesdy CP et al. Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J Am Soc Nephrol 2006; 17: 1181-1191.
5. Collins AJ. Influence of target hemoglobin in dialysis patients on morbidity and mortality. Kidney Int Suppl 2002; 80: 44-48.
6. Drueke TB, Locatelli F, Clyne N et al. Normalizationof hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006; 355: 2071-2085.
7. Singh AK, Szczech L, Tang KL et al. Correction of anemia with epoitin alfa in chronic kidney disease. N Engl J Med 2006; 355: 2085-2098.
8. Besarab A, Bolton WK, Browne JK et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998; 339: 584-590.
9. KDOQI. KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am J Kidney Dis 2007; 50: 471-530.
10. US Food and Drug Administration. http://www.fda.gov/bbs/topics/NEWS/2007/ NEW01740.
11. Fishbane S. What is needed to achieve a hemoglobin of 11.0-13.0 g/dl in end-stage renal disease. Blood Purif 2007; 25: 53-57.
12. Donauer J, Kö lblin D, Bek M et al. Ultrafiltration profiling and measurement of relative blood volume as strategies to reduce hemodialysis-related side effects. Am J Kidney Dis 2000; 36: 115-123.
13. Booth S, Chohan S, Curran JC et al. Whole blood viscosity and arterial thrombotic events in patients with systemic lupus erythematosus. Arthritis Rheum 2007; 57: 845-850.
14. Tzoulaki I, Murray GD, Lee AJ et al. Relative value of inflammatory, hemostatic, and rheological factors for incident myocardial infarction and stroke: the Edinburgh Artery Study. Circulation 2007; 115: 2119-2127.
15. Lee AJ, Mowbray PI, Lowe GD et al. Blood viscosity and elevated carotid intima-media thickness in men and women: the Edinburgh Artery Study. Circulation 1998; 97: 1467-1473.
16. Fishbane S. Erythropoiesis-stimulating agent treatment with full anemia correction: a new perspective. Kidney Int 2009; 75: 358-365.
17. Riedel E, Hampl H, Nündel M. Total correction of renal anemia in hemodialysis patients. Effects on amino acid metabolism. Proceedings of the 8th International Congress on Nutrition and Metabolism in Renal Disease 1997; 2: 1-4.
18. Hampl H, Hennig L, Rosenberger Ch et al. Effects of optimized heart failure therapy and anemia correction with epoetin b on left ventricular mass in hemodialysis patients. Am J Nephrol 2005; 25: 211-220.
19. Hampl H, Besarab A. Cardiovascular disease in the uremic patient. Kidney Blood Press Res 2005; 28: 270-371.
20. Hampl H, Hennig L, Gogoll L et al. Complete correction of anemia against cardiac events in uremic patients What is the problem? ASN San Francisco 2007; Abstract SU-FG 063.
21. Phrommintikul A, Haas SJ, Elsik M et al. Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet 2007; 369: 381-388.
22. Kannel WB. Mild hypertension as a cardiovascular risk factor. Compr Ther 1981; 7: 7-14.
23. Thamer M, Zhang Y, Kaufman J et al. Dialysis facility ownership and epoetin dosing in patients receiving hemodialysis. JAMA 2007; 297: 1667-1674
24. HR 6331: Medicare Improvements for Patients and Providers Act of 2008. http://www.govtrack.us/congress/bill.xpd?bill=h110-6331.
25. Kaufman JS. Subcutaneous erythropoietin therapy: efficacy and economic implications. Am J Kidney Dis 1998; 32(6 Suppl 4): S147-S151.
26. Fishbane S. Iron supplementation in renal anemia. Semin Nephrol 2006; 26: 319-324.
27. Bright R. Cases and observations, illustrative of renal disease accompanied with the secretion of albuminous urine. In: Guy's Hospital Reports 1, 1836, pp. 338-379.
28. Eschbach JW, Abdulhadi MH, Browne JK et al. Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial. Ann Intern Med 1989; 111: 992-1000.
29. National Kidney Foundation: DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease. Am J Kidney Dis 1997; 30: S194-S240.
30. Besarab A, Bolton WK, Browne JK et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998; 339: 584-590.
31. Kilpatrick RD, Critchlow CW, Fishbane S et al. Greater epoetin alfa responsiveness is associated with improved survival in hemodialysis patients. Clin J Am Soc Nephrol 2008; 3: 1077-1083.
32. Fishbane S, Besarab A. Mechinism of increased mortality risk with erythropoietin treatment to higher hemoglobin targets. Clin J Am Soc Nephrol 2007; 2: 1274-1282.
33. NKF-K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease: Update 2000. Am J Kidney Dis 2001; 37: S182-S238.
34. Collins AJ, Li S, St Peter W et al. Death, hospitalization, and economic associations among incident hemodialysis patients with hematocrit values of 36-39%. J Am Soc Nephrol 2001; 12: 2465-2473.
35. Regidor DL, Kopple JD, Kovesdy CP et al. Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J Am Soc Nephrol 2006; 17: 1181-1191
36. Medicare Payment Advisory Commission report to Congress, March 2003.
37. National Kidney Foundation: KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. Am J Kidney Dis 2006; 47: S1-S145.
38. Coyne DW. Influence of industry on renal guideline development. Clin J Am Soc Nephrol 2007; 2: 3-7.
39. Cotter D, Thamer M, Narasimhan K et al. Translating epoetin research into practice: the role of government and the use of scientific evidence. Health Aff 2006; 25: 1249-1259.
40. Singh AK, Szczech L, Tang KL et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006; 355: 2085-2098.
41. Drueke TB, Locatelli F, Clyne N et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006; 335: 2071-2084.
42. Remuzzi G, Ingelfinger JR. Correction of anemia\payoffs and problems. N Engl J Med 2006; 335: 2144-2146.
43. Pizzi LT, Patel NM, Maio V et al. Economic implications of non-adherence to treatment recommendations for hemodialysis patients with anemia. Dial Transpl 2006; 5: 1-7.
44. US Government Accountability Office. Report to the Chairman, Committee on Ways and Means, House of Representatives. End-stage renal disease. Bundling Medicare's payment for drugs with payment for all ESRD services would promote efficiency and clinical flexibility. November 2006.
45. National Kidney Foundation. KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease: 2007 Update of Hemoglobin Target. Am J Kidney Dis 2007; 50: 471-530.
46. Besarab A, Goodkin DA, Nissenson AR. The normal hematocrit study-follow-up. N Engl J Med 2008; 358: 433-444.
47. Coyne DW. From anemia trials to clinical practice: understanding the risks and benefits when setting goals for therapy. Semin Dial 2008; 21: 212-216.
48. Berwick DM. The science of improvement. JAMA 2008; 299: 1182-1184.